EGFR and colorectal carcinoma: In addition to RAS mutation, it has recently been reported that the primary CRC tumor site (right-sided or left-sided) was found to be associated with the therapeutic effect of anti-EGFR antibodies, and that the primary tumor site has increasingly been used as a biomarker to select the treatment regimen against mCRC [10, 11].